Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mestex
Basel, Basel-Stadt, Switzerlandmestex.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MTX-071 demonstrated long-lasting and significant analgesic effect and functional improvements compared to placebo, with a favorable safety profile in Phase II. Now in pivotal global Phase III trials for knee osteoarthritis pain. Received FDA Breakthrough Therapy Designation.
- Therapeutic areas
- Rheumatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
NovaQuest Capital Management (development cooperation post-acquisition by Grünenthal)Shionogi (licensing agreement for Japanese market via Grünenthal)
Beyond the preview
Go deeper on Mestex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mestex.